GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PhaseRx Inc (OTCPK:PZRXQ) » Definitions » Asset Turnover

PhaseRx (PhaseRx) Asset Turnover : 0.00 (As of Sep. 2017)


View and export this data going back to 2016. Start your Free Trial

What is PhaseRx Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. PhaseRx's Revenue for the three months ended in Sep. 2017 was $0.00 Mil. PhaseRx's Total Assets for the quarter that ended in Sep. 2017 was $7.62 Mil. Therefore, PhaseRx's Asset Turnover for the quarter that ended in Sep. 2017 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. PhaseRx's annualized ROE % for the quarter that ended in Sep. 2017 was -1,141.08%. It is also linked to ROA % through Du Pont Formula. PhaseRx's annualized ROA % for the quarter that ended in Sep. 2017 was -144.32%.


PhaseRx Asset Turnover Historical Data

The historical data trend for PhaseRx's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhaseRx Asset Turnover Chart

PhaseRx Annual Data
Trend Dec14 Dec15 Dec16
Asset Turnover
0.45 0.11 -

PhaseRx Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PhaseRx's Asset Turnover

For the Biotechnology subindustry, PhaseRx's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PhaseRx's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PhaseRx's Asset Turnover distribution charts can be found below:

* The bar in red indicates where PhaseRx's Asset Turnover falls into.



PhaseRx Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

PhaseRx's Asset Turnover for the fiscal year that ended in Dec. 2016 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2016 )/( (Total Assets (A: Dec. 2015 )+Total Assets (A: Dec. 2016 ))/ count )
=0/( (3.914+16.448)/ 2 )
=0/10.181
=0.00

PhaseRx's Asset Turnover for the quarter that ended in Sep. 2017 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2017 )/( (Total Assets (Q: Jun. 2017 )+Total Assets (Q: Sep. 2017 ))/ count )
=0/( (9.206+6.038)/ 2 )
=0/7.622
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


PhaseRx  (OTCPK:PZRXQ) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

PhaseRx's annulized ROE % for the quarter that ended in Sep. 2017 is

ROE %**(Q: Sep. 2017 )
=Net Income/Total Stockholders Equity
=-11/0.964
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-11 / 0)*(0 / 7.622)*(7.622/ 0.964)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*7.9066
=ROA %*Equity Multiplier
=-144.32 %*7.9066
=-1,141.08 %

Note: The Net Income data used here is four times the quarterly (Sep. 2017) net income data. The Revenue data used here is four times the quarterly (Sep. 2017) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

PhaseRx's annulized ROA % for the quarter that ended in Sep. 2017 is

ROA %(Q: Sep. 2017 )
=Net Income/Total Assets
=-11/7.622
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-11 / 0)*(0 / 7.622)
=Net Margin %*Asset Turnover
= %*0
=-144.32 %

Note: The Net Income data used here is four times the quarterly (Sep. 2017) net income data. The Revenue data used here is four times the quarterly (Sep. 2017) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


PhaseRx Asset Turnover Related Terms

Thank you for viewing the detailed overview of PhaseRx's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


PhaseRx (PhaseRx) Business Description

Traded in Other Exchanges
N/A
Address
410 West Harrison Street, Suite 300, Seattle, WA, USA, 98119
PhaseRx Inc is a biopharmaceutical company. It is developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, or i-ERT. The approach is enabled by proprietary Hybrid messenger RNA, or mRNA, Technology platform, which allows synthesis of the missing enzyme inside the cell. The product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency, or OTCD, argininosuccinate lyase deficiency, or ASL deficiency, and argininosuccinate synthetase deficiency, or ASS1 deficiency.
Executives
Gordon Brandt officer: Chief Medical Officer 410 WEST HARRISON STREET, SEATTLE WA 98119
Paul H Johnson director 3450 MONTE VILLA PARKWAY, BOTHELL WA 98053
Peggy V Phillips director C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
Michelle Renee Griffin director 19723 NE 65TH LANE, KIRKLAND WA 98033
Brian G Atwood director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Schmidt John A Jr director 300 THIRD ST, CAMBRIDGE X1 02142
Steven Gillis director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Samuel D Colella 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Robert Nelsen 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Rebecca B Robertson 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Barbara N Lubash 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Donald B Milder 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Charles M Warden 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Side Fund Iii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Venture Capital Iii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104

PhaseRx (PhaseRx) Headlines

From GuruFocus

Stocks Open Higher in Friday Session

By Omar Venerio Omar Venerio 10-13-2017

PhaseRX: The Latest Pick From a Legendary VC Firm

By $$$ Christopher Malcolm 05-24-2016